• Small kinase inhibitors have been developed to block

  2024-10-21

  

  Small kinase inhibitors have been developed to block AXL by interacting with the kinase cytoplasmic ATP binding site. Up to date, no AXL selective kinase inhibitors are marketed. As depicted in , some marketed kinase inhibitors such as Bosutinib and Cabozantinib or kinase inhibitors in clinical ph

• The combination of Aurora kinase inhibitors with standard ch

  2024-10-21

  

  The combination of Aurora kinase inhibitors with standard chemotherapeutics or radiotherapeutics are currently in progress, such as AZD1152 plus radiotherapy in various solid cancer models. In addition, Azzariti et al. found that AZD1152-HQPA enhanced oxaliplatin and gemcitabine effectiveness in the

• The analysis of the profile of protein phosphorylation in MM

  2024-10-21

  

  The analysis of the profile of protein phosphorylation in MMS-treated ntps confirmed that both the ATM and ATR pathways were activated in S-phase blocked cells. Interestingly, phosphorylation of Chk1 was observed 24h after MMS-treatment both in AT- and ATM-inhibited cells, whilst in the absence of

• It is now well established that the

  2024-10-21

  

  It is now well established that the cumulative exposure to endogenous estrogens throughout a woman's life, mainly due to her reproductive history, has an impact on the risk of hormone-dependent breast cancer (Lambertini et al., 2016). Prolonged exposure to estrogens in the case of early age at menar

• Histochemical analyses using antibody or cDNA

  2024-10-21

  

  Histochemical analyses using antibody or cDNA probes reveal the precise cellular location of the 12S-lipoxygenases in tissues of interest. An immunohistochemical study in various rat tissues showed specific expression of the leukocyte-type 12S-lipoxygenase in macrophages in lung and spleen [27]. In

• However a high triglyceride level was associated with

  2024-10-21

  

  However, a high triglyceride level was associated with dementia in a study with subjects aged ≥65 years (Raffaitin et al., 2009). In another study, the serum triglyceride levels of three different transgenic mouse strains mimicking AD were also evaluated within the progression of the pathology. In o

• Recently a Phase III study

  2024-10-21

  

  Recently, a Phase III study demonstrated that alectinib, the second-generation ALK inhibitor, might have a better response to ALK-rearrangement patients than crizotinib [10]. Should alectinib replace crizotinib as the frontline treatment for ALK-rearranged patients? Or should those patients be treat

• In large biopsies series from ALK NSCLC treated patients

  2024-10-21

  

  In large biopsies series from ALK+ NSCLC treated patients, the number of detected mutations increased after second generation ALKi (Gainor et al., 2016) and in one study were present in 56% of the entire cohort (Shaw et al., 2013b). For example, the rate of G1202R mutations increases from 2% in post

• Thus we presumed that ALDH

  2024-10-21

  

  Thus, we presumed that ALDH1A3 might play an important role in TMZ-chemoresistance in glioblastoma patients. As we expected, the glioblastoma cell lines and primary glioma HOE 33187 were more sensitive to TMZ treatment when ALDH1A3 was inhibited or depleted. Consistently, it has been shown that dow

• Gliomas and Aldehyde Dehydrogenase Aldehyde dehydrogenases A

  2024-10-21

  

  Gliomas and Aldehyde Dehydrogenase Aldehyde dehydrogenases (ALDHs) are key metabolic enzymes involved in regulation of glycolysis/gluconeogenesis pathways as well as in the detoxification of endogenous and exogenous aldehydes, regulating cell function and homeostasis. ALDHs play important roles in

• The results of cell culture models

  2024-10-21

  

  The results of cell culture models were further supported by in vivo studies in mice treated with PXR and/or AhR agonists, PCN and β-NF. In these mice, AhR-regulated cyp1a1, and cyp1a2 were suppressed by PXR activation as determined by real time Q-PCR (Fig. 3). The level of PXR mRNA was not changed

• br New AMPK activators Fenofibrate

  2024-10-19

  

  New AMPK activators Fenofibrate is a drug of the fibrate class used for the treatment of dyslipidemia [53] but is also an agent that could alleviate DN-induced alterations through AMPK activation (Fig. 2). Streptozotocin-induced diabetic rats treated with fenofibrate improved in not only renal fu

• We investigated the role of ABT treatment in MAPKinase activ

  2024-10-19

  

  We investigated the role of ABT 702 treatment in MAPKinase activation in mouse microglia in vitro. In Fig. 7D immunocytochemistry results revealed that Iba1 and p-ERK1/2 co-localized in LPS induced mouse microglia. In our previous study we have reported that LPS activates ERK1/2 phosphorylation (Ahm

• CNQX In conclusion we have demonstrated that

  2024-10-19

  

  In conclusion, we have demonstrated that ,-diaryl-1-pyrazolo[3,4-]pyrimidine-3,6-diamines represent a novel class of ACK1 inhibitors. The presence of a polar substituent at C-4 of the N-6 aryl ring was shown to be unnecessary for maintaining high levels of inhibitory activity. Furthermore, selectivi

• In summary the role of

  2024-10-19

  

  In summary, the role of 5-HT and different types of 5-HTRs in gating plasticity induction in neocortical circuits remains unclear, with variable and seemingly contradictory effects reported for LTP induction in cortical sensory fields (e.g., V1, enhanced LTP: Inaba et al., 2009, Kojic et al., 1997,

16127 records 72/1076 page Previous Next First page 上5页 7172737475 下5页 Last page